Artia Global Partners LP holds a focused book of 47 reported positions worth $526.0M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Alkermes PLC and trimmed Abivax Sa-ADR. Their largest long position is Abivax Sa-ADR at 13% of the reported non-option book. They also disclosed $15.8M in put options (a bearish bet), shown separately below and excluded from the non-option book. Cloning the disclosed picks since 2023 would be +44% (+10.8%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 6.5 points over this window.
Growth of $10,000 cloning Artia Global Partners LP's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Artia Global Partners LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Darwin Global Management, Ltd. | 5 / 47 | $3.8B |
| Patient Square Capital LP | 10 / 47 | $466.3M |
| Checkpoint Capital L.P. | 4 / 47 | $240.5M |
| Paradigm Biocapital Advisors LP | 8 / 47 | $3.3B |
| First Turn Management, LLC | 17 / 47 | $569.7M |
| Samsara BioCapital, LLC | 4 / 47 | $723.7M |
| Eagle Health Investments LP | 10 / 47 | $312.6M |
| Cormorant Asset Management, LP | 15 / 47 | $979.2M |
Ranked by the share of each fund's own book sitting in the names it shares with Artia Global Partners LP: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Abivax Sa SPONSORED ADS | $68.8M | 516.4K | 13.1% | ▼−14% Reduced · −84K sh | |
| 2 | Insmed Inc COM PAR $.01 | $62.8M | 589.1K | 11.9% | ▼−6.3% Reduced · −40K sh | |
| 3 | Trevi Therapeutics Inc COM | $41.2M | 2.21M | 7.8% | ▲+9.8% Added · +197K sh | |
| 4 | Brightspring Health Svcs Inc COM | $36.1M | 517.3K | 6.9% | ▲+862% Added · +464K sh | |
| 5 | Revolution Medicines Inc COM | $34.7M | 185.4K | 6.6% | ▲+48% Added · +60K sh | |
| 6 | Argenx SE SPONSORED ADR | $27.6M | 29.7K | 5.2% | —Held | |
| 7 | Alkermes PLC SHS | $23.5M | 449.0K | 4.5% | ▲New New position | |
| 8 | Travere Therapeutics Inc COM | $19.3M | 339.0K | 3.7% | ▲+380% Added · +268K sh | |
| 9 | AstraZeneca PLC ORD | $18.7M | 98.4K | 3.5% | ▲+3.1% Added · +3K sh | |
| 10 | Newamsterdam Pharma Company ORDINARY SHARES | $17.1M | 503.9K | 3.2% | —Held | |
| 11 | Dianthus Therapeutics Inc COM | $15.9M | 163.0K | 3.0% | —Held | |
| 12 | Quest Diagnostics Inc COM | $13.8M | 65.1K | 2.6% | ▲+60% Added · +24K sh | |
| 13 | Ionis Pharmaceuticals Inc COM | $11.4M | 144.4K | 2.2% | —Held | |
| 14 | Eyepoint Inc COM NEW | $11.0M | 767.1K | 2.1% | —Held | |
| 15 | Alumis Inc COM | $7.8M | 278.5K | 1.5% | ▼−14% Reduced · −47K sh | |
| 16 | Viking Therapeutics Inc COM | $7.1M | 180.7K | 1.3% | —Held | |
| 17 | Celcuity Inc COM | $6.2M | 59.3K | 1.2% | ▲+281% Added · +44K sh | |
| 18 | Cytokinetics Inc COM NEW | $6.0M | 70.7K | 1.1% | ▲+334% Added · +54K sh | |
| 19 | Merck & Co Inc COM | $6.0M | 46.7K | 1.1% | —Held | |
| 20 | Rapport Therapeutics Inc COM | $5.8M | 138.5K | 1.1% | —Held | |
| 21 | Johnson & Johnson COM | $5.7M | 22.6K | 1.1% | —Held | |
| 22 | Guardant Health Inc COM | $5.7M | 38.1K | 1.1% | ▲New New position | |
| 23 | Absci Corporation COM | $5.4M | 464.4K | 1.0% | ▲New New position | |
| 24 | Scholar Rock Hldg Corp COM | $5.3M | 96.3K | 1.0% | —Held | |
| 25 | Sionna Therapeutics Inc COM | $5.3M | 119.7K | 1.0% | —Held | |
| 26 | Ascendis Pharma A/s ORD SHS | $4.7M | 17.7K | 0.9% | ▲New New position | |
| 27 | Roivant Sciences Ltd SHS | $4.6M | 129.8K | 0.9% | —Held | |
| 28 | Palisade Bio Inc COM | $4.2M | 1.99M | 0.8% | —Held | |
| 29 | Edgewise Therapeutics Inc COM | $4.0M | 98.8K | 0.8% | ▲+51% Added · +33K sh | |
| 30 | Biogen Inc COM | $4.0M | 18.4K | 0.8% | —Held | |
| 31 | Xenon Pharmaceuticals Inc COM | $3.9M | 65.0K | 0.7% | —Held | |
| 32 | Belite Bio Inc SPONSORED ADS | $3.8M | 25.0K | 0.7% | —Held | |
| 33 | Mineralys Therapeutics Inc COM | $3.7M | 137.8K | 0.7% | —Held | |
| 34 | Prokidney Corp SHS CL A | $3.7M | 1.81M | 0.7% | —Held | |
| 35 | Enliven Therapeutics Inc COM | $3.7M | 72.1K | 0.7% | ▲+245% Added · +51K sh | |
| 36 | Oruka Therapeutics Inc COM | $3.2M | 33.4K | 0.6% | ▲New New position | |
| 37 | Protagonist Therapeutics Inc COM | $2.8M | 23.0K | 0.5% | ▲+0.1% Added · +20 sh | |
| 38 | United Therapeutics Corp Del COM | $2.7M | 5.0K | 0.5% | —Held | |
| 39 | Bright Minds Biosciences Inc COM NEW | $2.7M | 38.4K | 0.5% | —Held | |
| 40 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $1.9M | 29.2K | 0.4% | —Held | |
| 41 | Compass Therapeutics Inc COM | $839K | 383.2K | 0.2% | ▲New New position | |
| 42 | Praxis Precision Medicines I COM NEW | $837K | 2.5K | 0.2% | —Held | |
| 43 | Kodiak Sciences Inc COM | $663K | 17.0K | 0.1% | —Held | |
| 44 | Tenax Therapeutics Inc COM NEW | $612K | 42.1K | 0.1% | —Held | |
| 45 | Nuvalent Inc COM | $605K | 4.9K | 0.1% | —Held | |
| 46 | Pepgen Inc COM | $370K | 205.3K | 0.1% | —Held | |
| 47 | Spyre Therapeutics Inc COM NEW | $355K | 4.0K | 0.1% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1937964/holdings"
Use Arkolith to show Artia Global Partners LP's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $15.8M | 100K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the non-option book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 48 | $541.9M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 50 | $499.4M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 55 | $705.8M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 51 | $630.9M | 13F-HR/A |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 37 | $415.6M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 45d | 38 | $395.1M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 37 | $279.8M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 45 | $366.9M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 46 | $517.3M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 49 | $497.5M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 31 | $343.7M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 27 | $240.6M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 45d | 34 | $290.1M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 36 | $270.6M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 45d | 25 | $262.4M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.